Sunday, June 24, 2018

MSF Challenges Gilead Hepatitis C Patent In China; Intellectual Property Watch, June 19, 2018

Intellectual Property Watch; MSF Challenges Gilead Hepatitis C Patent In China

"According to the [Médecins Sans Frontières (MSF, Doctors Without Borders) press] release, “Gilead launched the sofosbuvir/velpatasvir combination at a price of US$51,000 for a 12-week treatment course in the United Kingdom, whereas the same treatment course is available for as low as $286 in India from generic manufacturers. In China, this combination was registered in May 2018, but Gilead has not yet announced its price.”

No comments: